Deep-pocketed investors have adopted a bearish approach towards Dell Technologies (NYSE:DELL), and it's something market players shouldn't ignore. Our tracking of public options records at Benzinga unveiled this significant move today. The identity of these investors remains unknown, but such a substantial move in DELL usually suggests something big is about to happen.We gleaned this information from our observations today when Benzinga's options scanner highlighted 10 extraordinary options activities for D ...

Investors might want to bet on Plexus (PLXS) , as it has been recently upgraded to a Zacks Rank #1 (Strong Buy). An upward trend in earnings estimates -- one of the most powerful forces impacting stock prices -- has triggered this rating change.A company's changing earnings picture is at the core of the Zacks rating. The system tracks the Zacks Consensus Estimate -- the consensus measure of EPS estimates from the sell-side analysts covering the stock -- for the current and following years.The power of a cha ...

Momentum investing revolves around the idea of following a stock's recent trend in either direction. In "long context," investors will be essentially be "buying high, but hoping to sell even higher." With this methodology, taking advantage of trends in a stock's price is key; once a stock establishes a course, it is more than likely to continue moving that way. The goal is that once a stock heads down a fixed path, it will lead to timely and profitable trades.While many investors like to look for momentum i ...

Investors might want to bet on Simply Good Foods (SMPL) , as it has been recently upgraded to a Zacks Rank #1 (Strong Buy). This rating change essentially reflects an upward trend in earnings estimates -- one of the most powerful forces impacting stock prices.The Zacks rating relies solely on a company's changing earnings picture. It tracks EPS estimates for the current and following years from the sell-side analysts covering the stock through a consensus measure -- the Zacks Consensus Estimate.Individual i ...

Momentum investing is all about the idea of following a stock's recent trend, which can be in either direction. In the "long context," investors will essentially be "buying high, but hoping to sell even higher." And for investors following this methodology, taking advantage of trends in a stock's price is key; once a stock establishes a course, it is more than likely to continue moving in that direction. The goal is that once a stock heads down a fixed path, it will lead to timely and profitable trades.Whil ...

Exponent (EXPO) could be a solid addition to your portfolio given its recent upgrade to a Zacks Rank #2 (Buy). This rating change essentially reflects an upward trend in earnings estimates -- one of the most powerful forces impacting stock prices.The sole determinant of the Zacks rating is a company's changing earnings picture. The Zacks Consensus Estimate -- the consensus of EPS estimates from the sell-side analysts covering the stock -- for the current and following years is tracked by the system.Since a ...

Core Insights - BD reported earnings per share (EPS) of $2.91, exceeding estimates of $2.82, indicating strong financial performance in fiscal 2026 [2] - Revenue increased by 1.6% to $5.3 billion, surpassing the estimated $5.15 billion, with a foreign exchange-neutral revenue rise of 0.4% [2] - The merger with Waters Corporation aims to enhance shareholder value and is expected to contribute to gross margin expansion [3] Financial Performance - BD's price-to-earnings (P/E) ratio is approximately 35.87, indicating a premium investors are willing to pay for earnings [5] - The price-to-sales ratio stands at about 2.74, while the enterprise value to sales ratio is 3.58, reflecting the value placed on its sales [5] - The debt-to-equity ratio is approximately 0.76, suggesting a balanced approach to financing assets [5] Strategic Initiatives - The merger with Waters Corporation combines BD's Biosciences and Diagnostic Solutions business, focusing on innovation and productivity [3] - Tom Polen, BD's chairman and CEO, expressed confidence in the company's future prospects and affirmed revenue growth guidance for fiscal year 2026 [4]

Paris, February 9, 2026, 7:00 p.m. CET – Audacia (FR00140059B5 – ALAUD), a private equity company specializing in Development Capital, Real Estate Capital and Innovation Capital, recognized for its pioneering investment theses, notably in Quantum technologies and Aerospace & Defense, announces the successful completion of its capital increase with shareholders’ preferential subscription rights (the “PSR”) launched on January 20, 2026 (the “Rights Issue”). As part of this transaction, Audacia raised total gr ...

Agenus to Present New Data at AACR-IO Exploring Systemic and Tumor Inflammation Biomarkers with BOT/BAL in Immunologically Cold TumorsFeb 9, 2026 1:00 PM Eastern Standard Time# Agenus to Present New Data at AACR-IO Exploring Systemic and Tumor Inflammation Biomarkers with BOT/BAL in Immunologically Cold TumorsShare---LEXINGTON, Mass.--([BUSINESS WIRE])-- [Agenus Inc]. (Nasdaq: AGEN), a leader in immuno-oncology, today announced that new translational and clinical biomarker analyses from its botensilimab (BO ...

It's time for the big three. Three stocks, three charts, three trades. Rick Ducat, of course, joining us to take us through the charts. Here to take us through the trades is Scott Bower from Prosper Trading Academy.Scott, always great to have you with us. You know, would love your your thoughts on our start to the week in the green, although the Dow dipping just slightly below the unchanged line right now. You maybe looking for a bit of direction with all the data we've got coming out this week.Yeah, I thin ...